Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Beverly Hospital
mi
from
Beverly, MA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Beverly Hospital
mi
from
Beverly, MA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Boston Med Ctr
mi
from
Boston, MA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Lahey Hospital and Medical Center
mi
from
Burlington, MA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Addison Gilbert Hospital
mi
from
Gloucester, MA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Addison Gilbert Hospital
mi
from
Gloucester, MA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Bixby Medical Center
mi
from
Adrian, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Bixby Medical Center
mi
from
Adrian, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hickman Cancer Center
mi
from
Adrian, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hickman Cancer Center
mi
from
Adrian, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint John Hospital and Medical Center
mi
from
Detroit, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Green Bay Oncology - Escanaba
mi
from
Escanaba, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Green Bay Oncology - Escanaba
mi
from
Escanaba, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Weisberg Cancer Treatment Center
mi
from
Farmington Hills, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Weisberg Cancer Treatment Center
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hurley Medical Center
mi
from
Flint, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Genesys Hurley Cancer Institute
mi
from
Flint, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Green Bay Oncology - Iron Mountain
mi
from
Iron Mountain, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Green Bay Oncology - Iron Mountain
mi
from
Iron Mountain, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Allegiance Health
mi
from
Jackson, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Borgess Medical Center
mi
from
Kalamazoo, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
West Michigan Cancer Center
mi
from
Kalamazoo, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Sparrow Hospital
mi
from
Lansing, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Mary Mercy Hospital
mi
from
Livonia, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mercy Memorial Hospital
mi
from
Monroe, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mercy Memorial Hospital
mi
from
Monroe, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Mary's of Michigan
mi
from
Saginaw, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Sanford Clinic North-Bemidgi
mi
from
Bemidji, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Sanford Clinic North-Bemidgi
mi
from
Bemidji, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Fairview Ridges Hospital
mi
from
Burnsville, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mercy Hospital
mi
from
Coon Rapids, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Fairview Southdale Hospital
mi
from
Edina, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Unity Hospital
mi
from
Fridley, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hutchinson Area Health Care
mi
from
Hutchinson, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hutchinson Area Health Care
mi
from
Hutchinson, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Health Partners Inc
mi
from
Minneapolis, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Health Partners Inc
mi
from
Minneapolis, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
New Ulm Medical Center
mi
from
New Ulm, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
New Ulm Medical Center
mi
from
New Ulm, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
The Mayo Clinic
mi
from
Rochester, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Regions Hospital
mi
from
Saint Paul, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
United Hospital
mi
from
Saint Paul, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
United Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Lakeview Hospital
mi
from
Stillwater, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Lakeview Hospital
mi
from
Stillwater, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Ridgeview Medical Center
mi
from
Waconia, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Rice Memorial Hospital
mi
from
Willmar, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Rice Memorial Hospital
mi
from
Willmar, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Parkland Health Center-Bonne Terre
mi
from
Bonne Terre, MO
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Parkland Health Center-Bonne Terre
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
CoxHealth Cancer Center
mi
from
Branson, MO
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
CoxHealth Cancer Center
mi
from
Branson, MO
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Francis Medical Center
mi
from
Cape Girardeau, MO
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Francis Medical Center
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials